Spectrum Pharma (SPPI) reported earnings on Mon 14 November 2016 (b/o)

** charts after earnings **

  

Spectrum Pharma beats by $0.10, beats on revs :

• Reports Q3 (Sep) loss of $0.07 per share, $0.10 better than the single analyst estimate of ($0.17); revenues rose 16.8% year/year to $33.4 mln vs the $28.43 mln Capital IQ Consensus. Product sales in the third quarter included: FUSILEV (levoleucovorin) net sales of $4.9 million, FOLOTYN (pralatrexate injection) net sales of $11.3 million, ZEVALIN (ibritumomab tiuxetan) net sales of $2.6 million, MARQIBO (vinCRIStine sulfate LIPOSOME injection) net sales of $1.9 million.